Form 4: Athira Pharma GC Sells Shares Post-RSU Vesting

Athira Pharma's General Counsel, Mark Worthington, sold 876 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Summary

• Mark Worthington, General Counsel and CCO of Athira Pharma, Inc. (ATHA), reported transactions involving company common stock.
• On December 31, 2025, 3,667 Restricted Stock Units (RSUs) vested and converted into 3,667 shares of common stock.
• These shares were part of an RSU grant of 11,000 units made on October 1, 2024, with vesting scheduled in three equal tranches.
• Following the vesting, Worthington directly owned 14,854 shares of common stock.
• On January 2, 2026, Worthington sold 876 shares of common stock at a weighted-average price of $6.88 per share.
• This sale was non-discretionary, executed solely to cover tax withholding and remittance obligations associated with the RSU vesting, as per mandatory 'sell to cover' policies.
• The remaining shares received from the RSU settlement are subject to a lock-up agreement with Cantor Fitzgerald & Co. related to a private placement in December 2025.
• The reported share numbers reflect adjustments due to a 10-for-1 reverse stock split completed by the Issuer on September 17, 2025.
• After these transactions, Worthington directly beneficially owned 13,978 shares of common stock.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving RSU vesting and a non-discretionary 'sell to cover' for tax purposes. While a sale reduces insider ownership, the context indicates it was not a discretionary move to divest. The lock-up agreement on remaining shares and the prior reverse stock split are noted, but the transaction itself is standard.

Positives

• The sale of shares was non-discretionary, solely for tax withholding purposes, indicating no intent to sell by the insider beyond tax obligations.
• Remaining shares from the RSU settlement are subject to a lock-up agreement, suggesting a commitment to holding the stock for a specified period.

Negatives

• A sale of shares, even for tax purposes, reduces the insider's direct ownership in the company.

Risks

• The company completed a 10-for-1 reverse stock split on September 17, 2025, which can sometimes be a sign of a struggling stock price or an attempt to meet listing requirements.
• A lock-up agreement is in place for shares received from RSU settlement, which could lead to future selling pressure once the lock-up expires, although it is a standard term for private placements.

Future Outlook

The filing notes that shares received upon RSU settlement are subject to a lock-up agreement in connection with a private placement in December 2025, which may impact future liquidity for those shares.

Management Comments

• The sale represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units pursuant to mandatory 'sell to cover' policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person.
• No additional shares of common stock were sold by the reporting person and the shares of Common Stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. entered into in connection with the Issuer's private placement in December 2025.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, specifically related to RSU vesting and subsequent tax-related sales. Such transactions are common in the biotechnology and pharmaceutical industries, where executive compensation often includes equity awards like RSUs. The mention of a reverse stock split and a private placement suggests recent corporate finance activities, which are also common for development-stage biotech companies seeking capital or managing share price.

Comparison to Industry Standards

• The 'sell to cover' mechanism for tax obligations upon RSU vesting is a standard practice across industries, including biotechnology, to manage tax liabilities without requiring the insider to use personal funds.
• Lock-up agreements following private placements are also standard to ensure stability post-financing and are common in the biotech sector where capital raises are frequent.
• Reverse stock splits, while not inherently negative, are often undertaken by companies, including those in the biotech sector, to increase share price, meet exchange listing requirements, or make the stock more attractive to institutional investors. For example, companies like Sorrento Therapeutics (SRNE) and Cassava Sciences (SAVA) have also executed reverse stock splits in the past under various circumstances.

Stakeholder Impact

• Shareholders: The sale of shares by an insider, even for tax purposes, slightly increases the float and could be perceived negatively if not understood as non-discretionary. The lock-up agreement provides some stability for the shares involved in the private placement. The reverse stock split impacts share count and price per share.
• Employees (specifically Mark Worthington): The vesting of RSUs represents a realization of compensation, and the 'sell to cover' mechanism facilitates tax compliance.

Next Steps

• Monitor the expiration of the lock-up agreement on the RSU-settled shares from the December 2025 private placement.
• Observe future insider filings for any discretionary sales or purchases by management.

Key Dates

Recommendation

This Form 4 details a routine, non-discretionary 'sell to cover' transaction by an insider following RSU vesting. Such transactions are common and generally do not signal a change in management's outlook or the company's fundamentals. The mention of a reverse stock split and a private placement indicates recent corporate finance activities, but this specific filing does not provide enough new information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of Athira Pharma's operational and financial performance.

Keywords

Athira Pharma, ATHA, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Sale, Tax Withholding, Reverse Stock Split, Corporate Governance, Biotechnology, Pharmaceuticals